Navigation Links
Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Date:9/30/2008

proval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit http://www.bioheartinc.com.

Footnotes:

(1) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post-Myocardial Infarction(s)

(2) The MYOSTAR(TM) Injection Catheter is not available for sale in the U.S. It is in use in IND investigations

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company

Forward Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect",

"believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
3. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 FDNA® ... analysis will exhibit at the 2014 ASHG meeting, booth ... FDNA will present the latest version of Face2Gene - ... facial analysis technology. Face2Gene facilitates the detection of facial ... facial photos. The new version of Face2Gene ...
(Date:9/23/2014)... HACKENSACK, N.J. , Sept. 23, 2014   ... million in a planned $7 million Series A funding ... participation from Med-Metrix. COTA is the first big data ... outcomes data and cost analysis for cancer care in ... funds will be used to expand development of the ...
(Date:9/23/2014)... 2014 Cerevast Therapeutics Inc., a privately ... of the first interim analysis of its ongoing ... Clotbust ER TM ultrasonic headframe ... independent Data Safety Monitoring Board (DSMB) has recommended ... "Clearing the pre-specified futility threshold and four independent ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 3
... May 3, 2012 Valeant Pharmaceuticals International, Inc. ... announced today that Valeant has agreed to acquire ... specialty pharmaceutical company focused on skincare products, for ... attainment of future revenue targets.  University Medical,s main ...
... Medical Group Inc. (Nasdaq: WWIN ) ("Winner ... retailer of high-quality medical dressings and consumer products made ... financial results for its second quarter 2012 on May ... conference call to discuss these results. Date ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT 2
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently ... services in Vancouver, BC. The company will provide services ... small maintenance project or a large-scale new installation project, ... the needs of the individual commercial client. Pro Ace ... an affordable price. As a result, businesses of all ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... New York, New York (PRWEB) September 23, 2014 ... move forward in courts around the country, Bernstein Liebhard ... District Court, Middle District of Florida on September 19th, ... claims from a case filed in that jurisdiction on ... breast growth) and other complications due to his use ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... drugs while in the hospital for a hemorrhagic stroke -- ... four times more likely to survive than people who weren,t ... taking the commonly used drugs known as statins were also ... a rehabilitation facility, the study reports. When it comes ...
Breaking Medicine News(10 mins):Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... well, sports commentators may describe them as being "hot" or ... the eye of the beholder, but a new study by ... that a streak of positive outcomes is likely to continue., ... the study analyzed five years of NBA free throws that ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- Older ... a greater risk of developing dementia than folks who believe ... the journal Neurology . Someday, "having people rate ... to determine a person,s risk of dementia, especially for people ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
... Oct. 5 (HealthDay News) -- The percentage of nursing ... flu shot is lower than the national goal, and the ... study finds. Brown University researchers examined annual patient records ... 2006-07 to 2008-09. The overall flu vaccination rate for ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Nearly one in ... center than 10 years ago due to closures of hospital ... had the greatest impact on black people, the poor, the ... San Francisco researchers. "Trauma centers aren,t just for ,certain, ...
... life experiences -- the ups and downs, and everything in ... emotional set point as adults, according to a new study ... suggests that, in addition to our genes, our life experiences ... "In this time of emphasis on genes for this ...
Cached Medicine News:Health News:Athletes' winning streaks may not be all in our -- or their -- heads 2Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:Nursing Homes Not Meeting Flu-Shot Goals, Study Says 2Health News:More Americans Face Longers Trips to ER 2Health News:Virginia Commonwealth University study: We are what we experience 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: